Published in final edited form as:

AIDS Behav. 2009 August ; 13(4): 731–737. doi:10.1007/s10461-009-9565-7.

Use of a Rapid HIV Home Test to Screen Sexual Partners: An Evaluation of Its Possible Use and Relative Risk

Ana Ventuneac¹, Alex Carballo-Diéguez¹, Cheng-Shiun Leu^{1,2}, Bruce Levin^{1,2}, Jose Bauermeister³, Emily Woodman-Maynard⁴, and Rebecca Giguere¹

¹HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, New York, USA

²Department of Biostatistics at Columbia University's Mailman School of Public Health, New York, USA

³Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA

⁴Clinical Psychology, Fordham University, New York, USA

Abstract

We estimated the HIV risk reduction that could be attained by using a rapid HIV home test (HT) to screen sexual partners versus using condoms in different proportions of anal intercourse (AI) occasions among men who have sex with men (MSM). Special attention was paid to the role of the window period during which infected cases go undetected. Our results show that if MSM engage in AI without condoms following a non-reactive HT result, they have lower chances of becoming infected by someone still in the window period than by following heuristics and using condoms inconsistently. For MSM who do not use condoms, use of HT as a screening device may be a useful risk reduction strategy. This advantage increases with higher HIV population prevalence. With higher HIV incidence, this strategy will not provide any advantage if condoms are used in as little as one out of four occasions.

Keywords

serosorting; rapid HIV test; risk reduction for HIV; gay men; men who have sex with men

INTRODUCTION

Evidence from recent studies on the sexual behavior of men who have sex with men (MSM) substantiates the assertion that some of the men who will not or cannot use condoms consistently are actively seeking and engaging in strategies to lower the risk of HIV transmission (Eaton et al., 2007; Elford et al., 2007; George et al., 2006; Golden, 2008; Halkitis et al., 2005; Mao et al., 2006; Parsons et al., 2005; Pinkerton, 2008; Poppen et al., 2005; Truong, 2006; Xia et al., 2006). Serosorting, defined as “the practice of preferentially choosing sex partners, or deciding not to use condoms with selected partners, based on their disclosed, concordant HIV status” (Golden, 2008, p. 212), has increased in popularity among HIV-negative MSM. However, recent studies have demonstrated that this practice is not effective and may actually increase men’s risk of HIV transmission (Eaton et al., 2007; Golden, 2008;

Pinkerton, 2008). This may occur if, for example, assumptions about one's own status are inaccurate (Eaton et al., 2007; Golden, 2008; Pinkerton, 2008), as may be the case if one is tested for HIV infrequently. A recent study found that testing intervals were wide for the majority of MSM occurring 14 months, on average, after the last test (Eaton, 2007); knowledge of one's own HIV status may be inaccurate if such a large interval is the norm and the individual engages in frequent HIV risk behavior.

Other studies have documented a widespread lack of accurate knowledge about one's own HIV status. MacKeller and colleagues (2005), using data collected from MSM, ages 15 – 29, at 263 randomly sampled venues in six US cities between 1994–2000, found that the majority of MSM who tested positive were unaware of their infection. Estimates indicate that, compared to people who are aware of their infection, those who are unaware of their status engage in greater sexual risk behaviors (Marks et al., 2005), and contribute to new infections disproportionately (Marks et al., 2006).

Various efforts are underway to increase the number of individuals who are regularly tested for the virus in the US (Branson et al., 2006), including making a rapid HIV test available for over-the-counter (OTC) use (Huff, 2005; Spielberg et al., 2004; Walensky and Paltiel, 2006; Wright and Katz, 2006). In November of 2005, the FDA started to consider licensing the OraQuick® ADVANCE™ Rapid HIV-1/2 Antibody Test, produced by OraSure Technologies Inc., for OTC sale (Richmond, 2005; Wright and Katz, 2006). This test is already approved by the FDA for use in testing facilities (Branson, 2000) and, if approved for OTC sale, could be self-administered in the privacy of one's own home using an oral fluid sample.

Despite the potential of a rapid HIV home test (HT) to reach individuals who might be reluctant to test themselves in a clinical setting, there is concern that it could be used to screen partners prior to sexual intercourse (Walensky and Paltiel, 2006; Goldstein, 2005; Harris, 2005). All antibody-based tests have a window period during which an infected individual tests negative (Fiebig et al., 2003); the home test is no exception. Most worrisome, this is a period of acute HIV infection during which a newly infected individual may be most contagious (Ahlgren et al., 1990; Jacquez et al., 1994; Pilcher et al., 2005; Rapatski et al., 2005; Wawer et al., 2005). If individuals decide to have sex without condoms after receiving a false non-reactive HT result, they might unknowingly put themselves at risk for infection.

Our study objective was to estimate the risk of HIV infection run by MSM if they use HT to screen potential sexual partners as compared to the risk run if they use condoms inconsistently. We used epidemiological and behavioral data from MSM to address the following research question: Given that antibodies are not likely to be detected during the three-month window period of primary or acute HIV infection, a high-infectivity stage during which the rate of transmission is thought to be highest as compared to the subsequent asymptomatic stage of infection, and considering that partners are likely to get a false-negative result during this period, would lack of condom use following a non-reactive HT result increase an individual's risk of HIV infection when compared to inconsistent condom use without HT use?

METHODS

We computed probabilities of becoming HIV infected based on various assumptions about model parameters to identify the point at which HT use to screen partners presents an increase in risk, particularly since antibodies are not likely to be detected by HT during the first three months of infection, relative to the protection provided by different levels of condom use (proportion of anal intercourse [AI] occasions that are protected with a condom). Similar models have been used to estimate infection risks based on different patterns of sexual behavior (Pinkerton and Abramson, 1993) and combinations of condom and microbicide use (Foss et

al., 2003), as well as to model the effect of HAART on infectiousness (Blower et al., 2000; Law et al., 2001). The model is static, in that it provides probabilities over a fixed period of time and assumes fixed infectivity, prevalence and incidence rates. Although we recognize the importance of calculating the risk of ever being infected over a lifespan, as suggested by Pinkerton and Abramson (1993), in this model we consider a one-year span for the sake of clarity. We assume statistical independence among the parameters (i.e., risk of HIV transmission is the same irrespective of the sexual occasion, whether it is the first or hundredth with an infected person; becoming infected from one partner is independent from becoming infected from other partners; Pinkerton and Abramson, 1993; Foss et al., 2003). Parameter estimates were identified through data resulting from *Frontiers in Prevention* (FIP), a study conducted in New York City with MSM who reported using condoms inconsistently or not at all (see Carballo-Diéguez et al., 2006; and Ventuneac et al., 2009 for a description of the study and sample), and a literature search using MEDLINE with the search terms “HIV incidence” and “HIV prevalence,” and narrowing results to “MSM” and “NYC epidemiology” (national studies were reviewed for NYC data) from 1998 to July of 2008. We also contacted the New York City Department of Health and Mental Hygiene for data on inconsistent condom users.

We defined the parameters used in the equations and how we obtained their estimates as follows. Let π be the probability that a sexual partner is HIV infected. We varied π to be 8.4%, 12.1%, 14%, 18%, and 20%, based on HIV prevalence estimates among MSM in NYC ranging from 8.4 – 18 percent (Catania et al., 2001; Centers for Disease Control and Prevention, 2001; Centers for Disease Control and Prevention, 2005; Koblin et al., 2000; Manning et al., 2000; McQuillan et al., 2006; Torian et al., 2002; Valleroy et al., 2000). Let δ be the probability that a sexual partner is in the acute infection stage. We used estimates of HIV incidence in NYC of 2.5% (2,500 per 100,000 person-years of follow up [p-y]; Nash, et al., 2005), 5.5% (5,500/100,000 p-y; preliminarily estimated among MSM who used condoms inconsistently from the National HIV Behavioral Surveillance data; personal communication with Christopher S. Murrill at New York City Department of Health, December 15, 2005), and 7.6% (7,600/100,000 p-y; Centers for Disease Control and Prevention, 2001) and divided these by 4π (which we varied as stated above) to reflect that the acute stage lasts typically three months (Ahlgren et al., 1990; Jacquez et al., 1994; Pilcher et al., 2005; Rapatski et al., 2005; Wawer et al., 2005). Let α be the probability of infection per contact (sex occasion) during the primary/acute infection, and let β be the probability of infection during the chronic asymptomatic stage. In our model, we estimated α and β to be 0.024 and .002 respectively, based on estimates of infectivity per contact in gay men previously used by Rapatski and colleagues (2005). Their stage ratios are similar to stage ratios of estimates found by Wawer and colleagues (2005; actual stage infectivities for vaginal intercourse were lower).

Let λ be the probability of condom breakage and slippage, estimated to be 5.4% in our calculations (2.7% for each; Grady and Tanfer, 1994), and let ϵ be the probability of HT correctly identifying HIV-positive partners, which we derived from sensitivity estimates provided by OraSure (sensitivity = 99.3%; 95% CI = 98.4% – 99.7%). Let γ_{HT} be the probability of having sex with a condom if HT indicates a reactive result. Based on findings from FIP data, 12% of HIV-negative men by self-report, will engage in unprotected AI with HIV infected partners. In our model, we conservatively anticipated an 88% condom usage rate for HT screeners with a reactive result for HIV, i.e., $\gamma_{HT} = 0.88$. Let μ_{HT} represent Foss and colleagues' (2003) concept of a method's use-effectiveness against HIV; it combines the probabilities of a true positive test result (sensitivity ϵ), having sex with a condom if HT indicates a positive result (with probability γ_{HT}), and condom non-breakage and non-slippage (with probability $1 - \lambda$). Thus, μ_{HT} is the probability that an individual is protected by condom use with a positive partner in the non-acute stage, per contact after HT use, assuming that HT-use is consistent with all partners. From the above definitions, $\mu_{HT} = \epsilon \gamma_{HT} (1 - \lambda)$, because the test must first show a reactive result (with probability ϵ), a condom must be used (with

probability γ_{HT}), and properly so (with probability $1 - \lambda$). Without use of HT, the condom use-effectiveness μ_C then equals $\gamma_C(1 - \lambda)$ where γ_C is the condom use consistency. This is because the condom is used with probability γ_C and is used properly with probability $(1 - \lambda)$. We varied γ_C from 0 to 75% in our calculation.

Let m be the number of partners per year. We used FIP data to estimate the number of male sexual partners in the previous two months of HIV-negative men in our sample ($Mdn = 7$, $M = 11.83$, $SD = 11.27$). In our model, we used the median (3.5 partners per month, therefore 42 per year) rather than the mean because the distribution was skewed. Finally, let n be the number of occasions per partner per year. Although reasonable assumptions could be made about the number of occasions per partner type (e.g., greater occasions with familiar partners versus a few one-night stands, as Pinkerton and Abramson [1993] considered in their model), we used FIP data to estimate the average number of anal intercourse occasions in the previous two months ($Mdn = 10$, $M = 17.03$, $SD = 26.51$) and estimated 1.43 occasions per partner per month in our calculations (therefore 17 per year).

The equations used to calculate the probability of HIV infection are presented below. If HT is used to screen partners (i.e., under the *HT condition*), the probability of HIV infection is:

$$p_{HT} = 1 - ((1 - \pi) + [\pi \delta \{1 - \alpha\}^n + \pi (1 - \delta) \{1 - \beta (1 - \mu_{HT})\}^n])^m$$

If HT is not used to screen partners, the probability of HIV infection is:

$$p_C = 1 - ((1 - \pi) + [\pi \delta \{1 - \alpha (1 - \mu_C)\}^n + \pi (1 - \delta) \{1 - \beta (1 - \mu_C)\}^n])^m$$

Notice that the probability of no HIV infection under the HT condition ($1 - p_{HT}$) is calculated as the disjoint union of three events: (i) partner not infected ($1 - \pi$); (ii) partner infected and in the acute stage ($\pi \delta$); and (iii) partner infected and in the chronic stage with probability $\pi (1 - \delta)$. The probability of no infection given an infected partner in the chronic stage in the HT condition is the term $1 - \beta (1 - \mu_{HT})$. This is in fact the complement of the probability of an infection given the conditions, which occurs if and only if there is a transmission (with probability β) in the event of an unprotected occasion (with probability $1 - \mu_{HT}$). It is important to note that we assume conservatively that if HT returns a non-reactive result, condoms will definitely not be used. Therefore, only one term is required to specify the probability of a successfully protected occasion (μ_{HT}). While HT is not used to screen partners, we vary levels of condom use consistency (γ_C) to calculate the condom use-effectiveness (μ_C).

RESULTS

Table 1 lists the probabilities of HIV infection for HT-use to screen sexual partners versus varying levels of condom use by various HIV prevalence and incidence estimates, while factoring in infectiousness. The results of our calculations show that the effectiveness of HT-use as a strategy in reducing one's risk of becoming HIV infected largely depends on prevalence and incidence of HIV in the population. The relative advantage of HT-use as a risk reduction strategy in comparison to no condom use is greater with higher prevalence. With lower prevalence (8.4%) and factoring in incidence of 2.5%, the probability of infection is approximately 8% lower under the HT condition versus no condom use (.103 vs. .180, respectively). The difference doubles (17.6%) with a prevalence of 20% (.128 for HT vs. .304 for no condom use, with 2.5% incidence factored in). This is mainly attributable to a device's ability to accurately detect antibodies to HIV after antibody seroconversion (Busch et al., 2003).

When condom use is inconsistent, HT-use provides some advantage (i.e., lower risk of HIV infection); however, underlying HIV prevalence and incidence rates determine the point at which such advantage is present. Under the 8.4% prevalence and 2.5% incidence condition, the point at which there is greater risk of becoming infected occurs for HT-use when condoms are used on half of occasions, meaning men would have lower chances of becoming HIV infected, if they used condoms on half or more of AI occasions than if they used HT to screen their partners before AI. HT-use would be advantageous to men who use condoms on less than half of AI occasions they engage in. With prevalence of 20%, increased risk occurs for HT-use only when condoms are used on 68% or more of occasions. In other words, the advantage of HT-use increases with higher prevalence in the population.

However, the relative advantage of HT-use compared to inconsistent condom use as a risk reduction strategy decreases with higher incidence in the population. This is attributable to the “window period” with its high infectiousness (Ahlgren et al., 1990; Jacquez et al., 1994; Pilcher et al., 2005; Rapatski et al., 2005; Wawer et al., 2005). In our calculations, the relative advantage of HT is lowest with high incidence and low prevalence populations, but still present over no condom use. With 7.6% incidence and 8.4% prevalence, there is a 5.4% lower probability of HIV infection for the HT condition versus no condom use. With 20% prevalence, the difference is 14%. The point at which there is greater risk of becoming infected under the HT-use condition occurs when condoms are used on a quarter of occasions for populations with high HIV incidence, highlighting the effectiveness of condom use in preventing HIV.

Although our calculations illustrate that, depending on HIV prevalence and incidence, HT-use could be beneficial for MSM who engage in unprotected AI, it is important to point out that we assumed consistent use of HT. This point must be stressed because realistic estimates need to be made about possible factors that can impact consistent HT-use with partners, including cost, availability, convenience, and partner characteristics. Further insights could be gained by calculating probabilities for different levels of HT-use.

DISCUSSION

Our mathematical modeling involved calculating the relative risk of using HT to screen sexual partners versus inconsistent condom use. The probability of HIV infection was calculated based on the following factors: HIV prevalence and incidence estimates; infectiousness; HT and condom use-effectiveness (HT-use was constant in our equation); condom breakage and slippage; HT sensitivity estimates; condom use if HT result is reactive; and number of partners and AI occasions. A key strength of our analyses is that the number of partners and number of AI occasions used in our calculations were not set arbitrarily; rather, they were estimated based on data collected in a prior study of HIV-uninfected MSM who are at high risk of HIV infection due to inconsistent or no condom use. Our calculations indicate that, as HIV prevalence increases in the population, there is advantage in using HT to screen partners versus low levels of condom use. However, the advantage dissipates with higher HIV incidence.

Our findings are in line with the work of Varghese and colleagues (2002) who estimated that, among MSM, engaging in sexual intercourse with a partner who tested negative reduced the relative risk of HIV infection as compared to sexual intercourse with untested partners. Based on their calculations for MSM, they noted that “[e]nsuring that a partner is HIV-negative can be one of the most effective strategies for prevention of HIV infection” (p. 42). However, the findings point to the importance of infectiousness during the acute stage (Eaton et al., 2007; Pinkerton, 2008) in determining risk, particularly for populations with high HIV incidence. If MSM engage in AI without condoms following a non-reactive HT result, they would have lower chances of becoming infected by someone still in the window period of infection than by using condoms in as much as five out of ten sexual occasions. HT as a sexual partner

screening device may be a useful risk reduction strategy for MSM who do not use condoms. This advantage increases with higher prevalence in the population. However, with higher incidence in the population, this strategy will not provide any advantage to men over and above condom use, if condoms are used in as little as one out of four occasions.

This study has some limitations. First, we did not include in our calculations other factors that could potentially impact the probability of HIV infection, such as the presence of sexually transmitted infections or circumcision status. Assumptions could be made for other parameters of interest (e.g., type of partner and thereby number of AI occasions). For example, reasonable assumptions could be made about the distribution of the number of AI occasions by partner-type, in that many more occasions may take place with a few “steady” partners and only a few occasions with “other” partners, such as one-night stands (Pinkerton and Abramson, 1993). Thus realistic patterns of sexual behavior with long-term versus short-term partners could be factored in. For example, Pinkerton and Abramson (1993) found that a substantial risk reduction can be made if condom-use is consistent with all one-night stands in high prevalence populations.

In addition, our approach was intentionally chosen to be conservative in order to provide an upper bound for the risk. We assumed that acutely-infected partners would not be detected by HT (i.e., HT would return a non-reactive result) and condoms will definitely not be used. In practice, other factors may decrease the risk of transmission: MSM may choose not to have sex after all, condoms may be used even with a non-reactive HT result, the kit may return a reactive result before the end of the three-month acute stage, etc. Lastly, we assumed constant HT-use with all partners. More realistic estimates could be made by varying HT-use consistency. Future research examining differing condom and HT use patterns would be useful.

Despite these limitations, our results provide important insights about the potential benefits of using HT to screen partners for low condom-users. Although consistent condom use can substantially reduce the probability of HIV infection, many individuals choose not to use condoms for various reasons (Carballo-Diéguez and Bauermeister, 2004; Bauermeister et al., 2009), and consistent condom use seems to be an unattainable ideal for some MSM. As technological developments become available, the question of how people will use them becomes very important. In this study, we have provided evidence that there is likely to be some advantage to employing a soon-to-be made available technology for individuals who choose to forego condom use in risky circumstances. Without careful study, individuals at the forefront of the battle with HIV may promote various strategies that are not at all beneficial and may in fact be harmful, as studies on Nonoxynol-9 have shown (Carballo-Diéguez et al., 2007; Gayle, 2000; Gross et al., 1998; Phillips and Zacharopoulos, 1998; Stephenson, 2000).

Alternative strategies to reduce the risk of HIV infection need to be studied to know how reasonable and effective a method may be for individuals who choose not to use condoms. Recent studies have begun to examine serosorting and its impact on HIV transmission more carefully (Eaton et al., 2007; Golden, 2008; Pinkerton, 2008). In the case of HT-use to screen partners, a great deal of work and attention is necessary, particularly for projecting use-effectiveness of HT (varying levels of use) and with different combinations of both HT and condom use to mimic more realistic circumstances. Similarly, considering sexual behavior by partner type would allow better informed strategies about when and who to screen. Of particular concern would be individuals who “migrate” from using condoms consistently to relying on HT-use, as Foss and colleagues (2003) have explored in their work on shifts in condom use after the introduction of microbicides.

There are clearly a number of issues that affect potential users differently (How? Where? When? With whom?). As Varghese and colleagues (2002) have noted, all sex acts have some

level of risk for HIV, and prevention efforts could benefit from estimates of the magnitude of risk reduction derived from various choices, in order to be able to provide more accurate information on sexual decisions that can effectively reduce individuals' risk. Our inquiry maintained the exploration in the realm of the hypothetical rather than taking it a step further to conduct a systematic exploration on possible uses of HT with various types of partners and actual experimentation of HT-use with partners. This should be the next step in integrating biomedical and behavioral research to inform HIV prevention programs (Rosengarten et al., 2008).

Acknowledgments

We would like to thank the reviewer of this manuscript for providing invaluable recommendations for the mathematical model used in this study. We would also like to thank Christopher S. Murrill and Lucia V. Torian at the New York City Department of Health and Mental Hygiene, and Denis Nash at Columbia University's Mailman School of Public Health for providing estimates of HIV incidence among MSM. The study, Internet Use and HIV Risk among Men in New York City (*Frontiers in Prevention*), was supported by a grant from NIMH (R01 MH69333, Principal Investigator: Alex Carballo-Diéguez, Ph.D.). This research was also supported by a center grant from the National Institute of Mental Health to the HIV Center for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University (P30-MH43520; Principal Investigator: Anke A. Ehrhardt, Ph.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIMH or the NIH.

REFERENCES

- Ahlgren DJ, Gorny MK, Stein AC. Model-based optimization of infectivity parameters: A study of the early epidemic in San Francisco. *Journal of Acquired Immune Deficiency Syndromes* 1990;3:631–643. [PubMed: 2338619]
- Bauermeister JA, Carballo-Diéguez A, Ventuneac A, Dolezal C. Assessing motivation to engage in intentional condomless anal intercourse in HIV-risk contexts (“bareback sex”) among men who have sex with men. *AIDS Education & Prevention* 2009;21(2):156–168. [PubMed: 19397437]
- Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. *Science* 2000;287:650–654. [PubMed: 10649998]
- Branson BM. Rapid Tests for HIV Antibody. *AIDS Reviews* 2000;2:76–83.
- Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings. *MMWR* 2006;55:1–16. [PubMed: 16988643]
- Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR. Time course detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. *Transfusion* 2003;35:91–97. [PubMed: 7825218]
- Carballo-Diéguez A, Bauermeister JA. “Barebacking”: Intentional condomless anal sex in HIV-risk contexts - Reasons for and against it. *Journal of Homosexuality* 2004;47(1):1–16.
- Carballo-Diéguez A, Dowsett G, Ventuneac A, Remien RH, Balan I, Dolezal C, Luciano O, Lin P. Cybercartography of popular Internet sites used by New York City MSM interested in bareback sex. *AIDS Education and Prevention* 2006;18:475–489. [PubMed: 17166075]
- Carballo-Diéguez A, O'Sullivan L, Lin P, Dolezal C, Pollack L, Catania J. Awareness and attitudes regarding microbicides and Nonoxynol-9 use in a probability sample of gay men. *AIDS and Behavior* 2007;11:271–276. [PubMed: 16775772]
- Catania JA, Osmond D, Stall RD, Pollack L, Paul JP, Blower S, Binson D, Canchola JA, Mills TC, Fisher L, Choi KH, Porco T, Turner C, Blair J, Henne J, Bye LL, Coates TJ. The continuing HIV epidemic among men who have sex with men. *American Journal of Public Health* 2001;91:907–914. [PubMed: 11392933]
- Centers for Disease Control and Prevention. HIV incidence among young men who have sex with men -- seven U.S. cities, 1994–2000. *MMWR* 2001;50:440–444. [PubMed: 11475380]

- Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men – 5 U.S. cities, June 2004–April 2005. *MMWR* 2005;54:596–601.
- Eaton LA, Kalichman SC, Cain D, Cherry C, Stearns H, Amaral C, Flanagan J, Pope H. Serosorting sexual partners and risk for HIV among men who have sex with men. *American Journal of Preventive Medicine* 2007;33:479–485. [PubMed: 18022064]
- Elford J, Bolding G, Sherr L, Hart G. No evidence of an increase in serosorting with casual partners among HIV-negative gay men in London, 1998–2005. *AIDS* 2007;21:243–245. [PubMed: 17197819]
- Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrandt C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS* 2003;17:1871–1879. [PubMed: 12960819]
- Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned? *AIDS* 2003;17:1227–1237. [PubMed: 12819525]
- Gayle HD. Notice to readers: CDC statement on study results of product containing nonoxynol-9. *MMWR* 2000;49:717–718.
- George C, Alary M, Otis J, Demers E, Mâsse B, Lavoie R, Remis RS, Turmel B, Vincelette J, Parent R, LeClerc R. and the Omega Study group: Omega Cohort, Montreal, Québec. Nonnegligible increasing temporal trends in unprotected anal intercourse among men who have sexual relations with other men in Montreal. *JAIDS* 2006;41:365–370. [PubMed: 16540939]
- Golden MR, Stekler J, Hughes JP, Wood RW. HIV serosorting in men who have sex with men: Is it safe? *JAIDS* 2008;49:212–218. [PubMed: 18769346]
- Goldstein, M. Not Out of the Woods. *The New York Times*. 2005 [2005 Dec 4]. Letters to the Editor [Internet]. 2005 Dec 4. Available from: <http://query.nytimes.com/gst/fullpage.html?res=9B00E3D91231F937A35751C1A9639C8B6>
- Grady WR, Tanfer K. Condom breakage and slippage among men in the United States. *Family Planning Perspectives* 1994;26:107–112. [PubMed: 8070546]
- Gross M, Buchbinder SP, Celum C, Hagerty P, Seage G. HIVNET Vaccine Preparedness Study Protocol Team. Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? *Sexually Transmitted Diseases* 1998;25:296–302. [PubMed: 9662763]
- Halkitis PN, Green KA, Remien RH, Stirratt MJ, Hoff CC, Wolitski RJ, Parsons JT. Seroconcordant sexual partnerings of HIV seropositive men who have sex with men. *AIDS* 2005;19:S77–S86. [PubMed: 15838197]
- Harris, G. Test Adds New Twist to the Dating Game. *The New York Times*. 2005. [Internet]. 2005 Nov 27. Available from: <http://select.nytimes.com/gst/abstract.html?res=F3081EFC3C550C748EDDA80994DD404482>
- Huff B. FDA hearing on home HIV testing. *GMHC Treatment Issues* 2005;19:9. [PubMed: 16909508]
- Jacquez JA, Koopman JS, Simon CP, Longini IM. Role of the primary infection in epidemics of HIV infection in gay cohorts. *Journal of Acquired Immune Deficiency Syndromes* 1994;7:1169–1184. [PubMed: 7932084]
- Koblin BA, Torian LV, Guilin V, Ren L, MacKellar DA, Valleroy LA. High prevalence of HIV infection among young men who have sex with men in New York City. *AIDS* 2000;14:1793–1800. [PubMed: 10985317]
- Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modeling the effect of combination antiretroviral treatments on HIV incidence. *AIDS* 2001;15:1287–1294. [PubMed: 11426074]
- MacKellar DA, Valleroy LA, Secura GM, Behel S, Bingham T, Celentano DD, Koblin B, LaLota M, McFarland W, Shehan D, Thiede H, Torian L, Janssen RS. for the Young Men's Survey Study Group. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young men who have sex with men: Opportunities for advancing HIV prevention in the third decade of HIV/AIDS. *Journal of Acquired Immune Deficiency Syndromes* 2005;38:603–614. [PubMed: 15793373]
- Manning SE, Thorpe LE, Ramaswamy C, Hajat A, Marx MA, Karpati AM, Mostashari F, Pfeiffer MR, Nash D. Estimation of HIV prevalence, risk factors, and testing frequency among sexually active

- men who have sex with men, aged 18–64 years—New York City, 2002. *Journal of Urban Health* 2000;84:212–225. [PubMed: 17295058]
- Mao L, Crawford JA, Hoppers HJ, Prestage GP, Grulich AE, Kaldor JM, Kippax SC. “Serosorting” in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. *AIDS* 2006;20:1204–1206. [PubMed: 16691075]
- Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. *AIDS* 2006;20:1447–1450. [PubMed: 16791020]
- Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: Implications for HIV prevention programs. *Journal of Acquired Immune Deficiency Syndromes* 2005;39:446–453. [PubMed: 16010168]
- McQuillan GM, Kruszon-Moran D, Kottiri BJ, Kamimoto LA, Lam L, Cowart MF, Hubbard M, Spira TJ. Prevalence of HIV in the US household population : The National Health and Nutrition Examination Surveys, 1988 to 2002. *Journal of Acquired Immune Deficiency Syndromes* 2006;41:651–656. [PubMed: 16652040]
- Nash D, Bennani Y, Ramaswamy C, Torian L. Estimates of HIV incidence among persons testing for HIV using the sensitive/less sensitive enzyme immunoassay, New York City, 2001. *Journal of Acquired Immune Deficiency Syndromes* 2005;39:102–111. [PubMed: 15851920]
- Parsons JT, Schrimshaw EW, Wolitski RJ, Halkitis PN, Purcell DW, Hoff CC, Gómez CA. Sexual harm reduction practices of HIV-seropositive gay and bisexual men: Serosorting, strategic positioning, and withdrawal before ejaculation. *AIDS* 2005;19:S13–S25. [PubMed: 15838191]
- Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice - interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Contraception* 1998;57:341–348. [PubMed: 9673842]
- Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, Ashby R, O'Dowd JO, McPherson JT, Stalzer B, Hightow L, Miller WC, Eron JJ Jr, Cohen MS, Leone PA. Detection of acute infections during HIV testing in North Carolina. *New England Journal of Medicine* 2005;352:1873–1883. [PubMed: 15872202]
- Pinkerton SD. Acute HIV infection increases the dangers of serosorting. *American Journal of Preventive Medicine* 2008;35:184. [PubMed: 18617087]
- Pinkerton SD, Abramson PR. Evaluating the risks: A Bernoulli process model of HIV infection and risk reduction. *Evaluation Review* 1993;17:504–528.
- Poppen PJ, Reisen CA, Zea MC, Bianchi FT, Echeverry JJ. Serostatus disclosure, seroconcordance, partner relationship, and unprotected anal intercourse among HIV-positive Latino men who have sex with men. *AIDS Education and Prevention* 2005;17:227–237. [PubMed: 16006209]
- Rapatski BL, Suppe F, Yorke JA. HIV epidemics driven by late disease stage transmission. *Journal of Acquired Immune Deficiency Syndromes* 2005;38:241–253. [PubMed: 15735440]
- Richmond, L. FDA considers at home HIV test kit. *The Circle*. 2005 Dec 8. Available at: <http://www.maristcircle.com/media/paper659/news/2005/12/08/Health/Fda-Considers.At.Home.Hiv.Test.Kit-1123392.shtml?noreferrer=200603301816&sourcedomain=www.maristcircle.com>
- Rosengarten M, Michaela M, Mykhalovskiy M, Imrie J. The challenges of technological innovation in HIV. *Lancet* 2008;372(9636):357–358. [PubMed: 18675674]
- Spielberg F, Levine RO, Weaver M. Self-testing for HIV: a new option for HIV prevention? *The Lancet Infectious Diseases* 2004;4:640–646. [PubMed: 15451493]
- Stephenson J. Widely used spermicide may increase, not decrease, risk of HIV transmission. *JAMA* 2000;284:949. [PubMed: 10944622]
- Torian LV, Makki HA, Menzies IB, Murrill CS, Weisfuse IB. HIV infection in men who have sex with men, New York City Department of Health sexually transmitted disease clinics, 1990–1999. *Sexually Transmitted Diseases* 2002;29:73–78. [PubMed: 11818891]
- Truong HM, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant RM, Louie B, McFarland W. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a

- suggestion of HIV serosorting? Sexually Transmitted Infections 2006;82:461–466. [PubMed: 17151031]
- Valleroy LA, MacKellar DA, Karon JM, Rosen DH, McFarland W, Shehan DA, Stoyanoff SR, LaLota M, Celentano DD, Koblin BA, Thiede H, Katz MH, Torian LV, Janssen RS. for the Young Men's Survey Study Group. HIV prevalence and associated risks in young men who have sex with men. JAMA 2000;284:198–204. [PubMed: 10889593]
- Varghese B, Maher JE, Peterman TA, Branson BM, Steketee R. Reducing the risk of sexual HIV transmission: Quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sexually Transmitted Diseases 2002;29:38–43. [PubMed: 11773877]
- Ventuneac A, Carballo-Diéguez A, Rowe MS, Frasca T, Nodin N, Balán I, Dolezal C, Remien RH, Dowsett GW. Online recruitment techniques for face-to-face interviews of men who have sex with men. 2009Manuscript submitted for publication
- Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Annals of Internal Medicine 2006;145:459–462. [PubMed: 16983134]
- Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases 2005;191:1403–1409. [PubMed: 15809897]
- Wright AA, Katz IT. Home testing for HIV. New England Journal of Medicine 2006;354:437–440. [PubMed: 16452553]
- Xia Q, Molitor F, Osmond DH, Tholandi M, Pollack LM, Ruiz JD, Catania JA. Knowledge of sexual partner's HIV serostatus and serosorting practices in a California population-based sample of men who have sex with men. AIDS 2006;20:2081–2089. [PubMed: 17053354]

Table 1
Probability of becoming HIV infected using HT to screen versus inconsistent condom use.

π (%)	γ_C	$\delta_{(2.5\%/4\pi)}$		$\delta_{(5.5\%/4\pi)}$		$\delta_{(7.6\%/4\pi)}$	
		p _{HT}	p _C	p _{HT}	p _C	p _{HT}	p _C
8.4	0		.180		.256		.304
	.25	.103	.143	.192	.207	.249	.249
	.50		.103		.152		.185
	.75		.060		.090		.110
12.1	0		.222		.294		.340
	.25	.111	.177	.199	.238	.256	.278
	.50		.128		.175		.207
	.75		.074		.103		.123
14	0		.242		.312		.357
	.25	.115	.194	.203	.254	.260	.293
	.50		.140		.187		.218
	.75		.081		.110		.130
18	0		.284		.350		.393
	.25	.124	.228	.211	.286	.267	.323
	.50		.166		.211		.241
	.75		.096		.125		.145
20	0		.304		.368		.410
	.25	.128	.245	.215	.301	.271	.338
	.50		.178		.223		.253
	.75		.104		.132		.152

Note. π = HIV prevalence; δ = HIV incidence/ 4π (e.g., $2.5\% \div (4 \times 8.4\%)$); γ_C = condom-use consistency; p_{HT} = probability of infection under the HT condition; p_C = probability of infection under various condom-use consistency levels (HT is not used to screen partners)